The Beauty Health Company (SKIN) exceeded Q2 2025 expectations with $78.2 million in revenue and $0.03 EPS, surprising analysts and leading to price target upgrades from TD Cowen, Jefferies, and Roth/MKM. The firm’s focus on provider engagement and innovation, including new booster launches and partnerships, is driving growth. SKIN is increasingly discussed among the best bear market stocks due to its steady margins and expanding consumables model. The company continues to expand its product lines strategically and has reinforced its convertible notes. For investors, SKIN offers resilience in the consumer health and wellness sector.

Read more at Yahoo Finance: The Beauty Health Company (SKIN) Smashes Q2 Expectations With Surprise Profit, $78.2M Revenue